home / stock / pbyi / pbyi quote
Last: | $2.94 |
---|---|
Change Percent: | -2.65% |
Open: | $3.03 |
Close: | $3.02 |
High: | $3.06 |
Low: | $2.9 |
Volume: | 170,785 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.94 | $3.03 | $3.02 | $3.06 | $2.9 | 170,785 | 07-05-2024 |
$3.02 | $3.08 | $3.02 | $3.1 | $3.01 | 126,584 | 07-04-2024 |
$3.02 | $3.08 | $3.02 | $3.1 | $3.01 | 126,584 | 07-03-2024 |
$3.1 | $3.25 | $3.1 | $3.34 | $3.0501 | 852,877 | 07-02-2024 |
$3.28 | $3.24 | $3.28 | $3.29 | $3.03 | 743,658 | 07-01-2024 |
$3.26 | $3.21 | $3.26 | $3.395 | $3.15 | 5,775,223 | 06-28-2024 |
$3.23 | $3.15 | $3.23 | $3.24 | $2.96 | 816,569 | 06-27-2024 |
$3.14 | $2.96 | $3.14 | $3.16 | $2.81 | 597,289 | 06-26-2024 |
$2.96 | $2.95 | $2.96 | $3 | $2.82 | 838,635 | 06-25-2024 |
$2.92 | $2.99 | $2.92 | $3.03 | $2.87 | 232,789 | 06-24-2024 |
$2.99 | $2.97 | $2.99 | $3.11 | $2.95 | 274,066 | 06-21-2024 |
$2.98 | $3.09 | $2.98 | $3.13 | $2.95 | 372,679 | 06-20-2024 |
$3.09 | $3.18 | $3.09 | $3.22 | $3.03 | 352,899 | 06-19-2024 |
$3.09 | $3.18 | $3.09 | $3.22 | $3.03 | 352,899 | 06-18-2024 |
$3.2 | $3.09 | $3.2 | $3.2 | $3.0855 | 193,082 | 06-17-2024 |
$3.11 | $3.31 | $3.11 | $3.34 | $3.09 | 214,217 | 06-14-2024 |
$3.32 | $3.6 | $3.32 | $3.72 | $3.28 | 570,138 | 06-13-2024 |
$3.595 | $3.58 | $3.595 | $3.67 | $3.4288 | 445,812 | 06-12-2024 |
$3.47 | $3.49 | $3.47 | $3.6 | $3.425 | 230,465 | 06-11-2024 |
$3.49 | $3.54 | $3.49 | $3.54 | $3.42 | 179,163 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000 ® Index at the conclusion of Russell Investments’ annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S....